Lipid Metabolism in COVID-19 Severe Pneumonia Compared With Severe Pneumonia Caused by Other Pathogen
NCT ID: NCT04435223
Last Updated: 2026-02-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
62 participants
OBSERVATIONAL
2020-04-07
2020-05-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Adipose Tissue in COVID-19
NCT04639440
Obesity and Mortality of Critically Ill Patients With COVID-19
NCT04425213
Association Between BMI and COVID-19
NCT04391738
Is Adipose Tissue a Reservoir for SARS-Cov2 Spread in Covid-19 Patients?
NCT04427878
Weight Gain and Adipose Tissue
NCT02703766
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
COVID-19 severe pneumonia
biological assays in particular on the lipid metabolism
bioassays carried out on samples already collected and conserved
Severe pneumonia due to other pathogene
biological assays in particular on the lipid metabolism
bioassays carried out on samples already collected and conserved
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
biological assays in particular on the lipid metabolism
bioassays carried out on samples already collected and conserved
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At admission or within 48 hours following hospital admission
* With 2 qSOFA criteria: MAP =\< 100 mmHg, Respiratory Rate \>= 22, Glasgow score \< 15 OR on mechanical ventilation OR under vasopressor
* Age \> 18
* affiliated to social security
Exclusion Criteria
* immunodepression
* Pathology known to cause severe lymphopenia
* hospitalisation within 3 month before inclusion AND sepsis
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire Dijon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chu Dijon Bourgogne
Dijon, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Nguyen M, Bourredjem A, Piroth L, Bouhemad B, Jalil A, Pallot G, Le Guern N, Thomas C, Pilot T, Bergas V, Choubley H, Quenot JP, Charles PE, Lagrost L, Deckert V, de Barros JP, Guinot PG, Masson D, Binquet C, Gautier T, Blot M; Lymphonie study group. High plasma concentration of non-esterified polyunsaturated fatty acids is a specific feature of severe COVID-19 pneumonia. Sci Rep. 2021 May 24;11(1):10824. doi: 10.1038/s41598-021-90362-9.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NGUYEN AOIc 2020
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.